C4XD is eligible to receive development and commercial milestone payments worth $385.8m from AstraZeneca.
Free Whitepaper Precision Medicine: Streamlining Treatments and Drug Development Precision medicine has the potential to radically change the way health…
This funding could offer patients treatments and digital technologies, which were found to be safe in trials.
According to the agreement, ADC Therapeutics will make an upfront payment to Biocytogen.
Get industry leading news, data and analysis delivered to your inbox